Immunocore makes progress in deal with GSK

UK-based biotech firm Immunocorehas achieved its first milestone in its major research and licensing agreement with UK pharma major GlaxoSmithKline (LSE: GSK) for multiple novel targets.

The achievement comes less than four months after the companies signed their agreement and triggers a first undisclosed milestone payment to Immunocore following the identification of a first lead candidate ImmTAC against one of the targets. Immunocore is responsible for all preclinical development activity and for initial clinical trials in patients while GSK will handle the remaining development and commercialization of the products.

Triggers milestone payment